ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

INDP Indaptus Therapeutics Inc

2,61
-0,03 (-1,14%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Indaptus Therapeutics Inc INDP NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,03 -1,14% 2,61 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,56 2,48 2,61 2,49 2,64
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/6/202414:00GLOBEIndaptus Therapeutics to Present Positive Data on Lead..
07/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:30EDGAR2Form 8-K - Current report
04/6/202414:00GLOBEIndaptus Therapeutics to Present New Positive Data on..
03/6/202414:00GLOBEIndaptus Therapeutics Announces New Positive Data from..
30/5/202414:00GLOBEIndaptus Therapeutics to Present at the Jefferies Global..
29/5/202414:00GLOBEIndaptus Therapeutics to Present New Cohort Data Confirming..
22/5/202414:00EDGAR2Form 8-K - Current report
22/5/202414:00GLOBEIndaptus Therapeutics Announces Completion of First Patient..
08/5/202414:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202414:05EDGAR2Form 8-K - Current report
08/5/202414:00GLOBEIndaptus Therapeutics Reports First Quarter 2024 Financial..
11/4/202413:30GLOBEIndaptus Therapeutics Presents Positive Mechanism of Action..
28/3/202413:00GLOBEIndaptus Therapeutics to Present at the MedInvest Biotech..
25/3/202413:30GLOBEIndaptus Therapeutics Previews Positive Mechanism of Action..
18/3/202413:00GLOBEIndaptus Therapeutics to Participate in Tribe Public Webinar..
13/3/202412:30GLOBEIndaptus Therapeutics Reports Fourth Quarter and Year-End..
04/3/202417:01EDGAR2Form 8-K - Current report
04/3/202413:30GLOBEIndaptus Therapeutics Announces Positive Results from Second..
15/2/202414:00GLOBEIndaptus Therapeutics to Present at the 2024 BIO CEO &..
08/2/202414:00GLOBEIndaptus Therapeutics Expands Digital Presence with Launch..
23/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202422:05EDGAR2Form 8-K - Current report
04/1/202414:00GLOBEEuropean Patent Office Approves Key Patent for Indaptus..
06/11/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:05EDGAR2Form 8-K - Current report
06/11/202322:01GLOBEIndaptus Therapeutics Reports Third Quarter 2023 Financial..
06/11/202314:13EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune..
31/10/202314:12EDGAR2Form 8-K - Current report
31/10/202314:01GLOBEIndaptus Therapeutics to Present Positive Pharmacodynamic..
27/9/202314:00GLOBEIndaptus Therapeutics to Present at the LD Micro Main Event..
26/9/202314:00GLOBERegistration Is Now Open For Tribe Public’s Webinar Event..
19/9/202314:00GLOBEIndaptus Therapeutics Doses First Patient in Second Cohort..
06/9/202314:05GLOBEIndaptus Therapeutics to Present at the H.C. Wainwright 25th..
17/8/202300:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202314:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202314:10EDGAR2Form 8-K - Current report
14/8/202314:00GLOBEIndaptus Therapeutics Reports Second Quarter 2023 Financial..
10/8/202314:45EDGAR2Form 8-K - Current report
10/8/202314:45GLOBEIndaptus Therapeutics Announces Opening of Next Cohort in..
07/8/202314:00GLOBEIndaptus Therapeutics Appoints Industry Veteran Roger..

Dernières Valeurs Consultées